Abstract
Fluoroquinolones (FQs) are important drugs to treat drug-resistant tuberculosis. In this review we integrated pharmacokinetic properties (PK) and microbiological susceptibility against M. tuberculosis and eventually evaluated the pharmcodynamic (PD) properties, as well as the influence of co-administered agents on these characteristics, for the currently used FQs (ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin) in TB treatment. Future FQs that are being developed may overcome the problems with FQs that are used in daily practice. Therefore PK and pharmacodynamic (PD) properties of novel FQs (clinafloxacin, garenoxacin, lomefloxacin, sitafloxacin, sparfloxacin, trovafloxacin, gemifloxacin, grepafloxacin and DC-159a) were evaluated in TB treatment as well. Integrating both excellent PK and PD properties, moxifloxacin, possibly at a higher dosage, may fulfil a far more important role in the treatment of multi-drug and early-generation FQ resistant TB than proposed in the current WHO guideline. Sparfloxacin, trovafloxacin and sitafloxacin are upcoming novel FQs that may be useful for drug-resistant TB based on their favourable PK properties or microbiological susceptibility against M. tuberculosis. Finally, the 8-methoxy moiety, as present in the chemical structure of MFX, will possibly provide DC- 159a with promising PK/PD characteristics and consequently this FQ may develop into a key FQ in future drug resistant TB treatment.
Keywords: Fluoroquinolones, drug-resistant tuberculosis, pharmacokinetics, pharmacodynamics, drug-drug interactions, M. tuberculosis, cerebrospinal fluid (CSF), DNA gyrase, biotransformation, HIV infection
Current Pharmaceutical Design
Title: Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Volume: 17 Issue: 27
Author(s): A. D. Pranger, J. W.C. Alffenaar and R. E. Aarnoutse
Affiliation:
Keywords: Fluoroquinolones, drug-resistant tuberculosis, pharmacokinetics, pharmacodynamics, drug-drug interactions, M. tuberculosis, cerebrospinal fluid (CSF), DNA gyrase, biotransformation, HIV infection
Abstract: Fluoroquinolones (FQs) are important drugs to treat drug-resistant tuberculosis. In this review we integrated pharmacokinetic properties (PK) and microbiological susceptibility against M. tuberculosis and eventually evaluated the pharmcodynamic (PD) properties, as well as the influence of co-administered agents on these characteristics, for the currently used FQs (ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin) in TB treatment. Future FQs that are being developed may overcome the problems with FQs that are used in daily practice. Therefore PK and pharmacodynamic (PD) properties of novel FQs (clinafloxacin, garenoxacin, lomefloxacin, sitafloxacin, sparfloxacin, trovafloxacin, gemifloxacin, grepafloxacin and DC-159a) were evaluated in TB treatment as well. Integrating both excellent PK and PD properties, moxifloxacin, possibly at a higher dosage, may fulfil a far more important role in the treatment of multi-drug and early-generation FQ resistant TB than proposed in the current WHO guideline. Sparfloxacin, trovafloxacin and sitafloxacin are upcoming novel FQs that may be useful for drug-resistant TB based on their favourable PK properties or microbiological susceptibility against M. tuberculosis. Finally, the 8-methoxy moiety, as present in the chemical structure of MFX, will possibly provide DC- 159a with promising PK/PD characteristics and consequently this FQ may develop into a key FQ in future drug resistant TB treatment.
Export Options
About this article
Cite this article as:
D. Pranger A., W.C. Alffenaar J. and E. Aarnoutse R., Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470200
DOI https://dx.doi.org/10.2174/138161211797470200 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imidazole and 1,2,4-Triazole-based Derivatives Gifted with Antitubercular Activity: Cytotoxicity and Computational Assessment
Current Topics in Medicinal Chemistry QSAR as a Random Event: Selecting of the Molecular Structure for Potential Anti-tuberculosis Agents
Anti-Infective Agents TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Identification of Proteins Interacting with Human SP110 During the Process of Viral Infections
Medicinal Chemistry Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
Current Pharmaceutical Design Design, Synthesis and Cytotoxicity of Chalcone Analogs Derived from 2-Phenylimino-3-phenylthiazolidin-4-one
Letters in Drug Design & Discovery A Novel Support Vector Machine Classifier Using Soft Computing Approach for Automated Classification of Emphysema, Bronchiectasis and Pleural Effusion Using Optimized Gabor Filter
Current Signal Transduction Therapy Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets QSAR Models for Anti-Malarial Activity of 4-Aminoquinolines
Current Computer-Aided Drug Design Health Benefits of Manuka Honey as an Essential Constituent for Tissue Regeneration
Current Drug Metabolism Controlling Pathogenic Gram-Negative Bacteria by Interfering with Their Biofilm Formation
Drug Design Reviews - Online (Discontinued) HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions
Current Immunology Reviews (Discontinued) Quinoxaline 1,4-di-N-Oxide and the Potential for Treating Tuberculosis
Infectious Disorders - Drug Targets Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular Insights into the Interaction of Ursolic Acid and Cucurbitacin from Colocynth with Therapeutic Targets of <i>Mycobacterium tuberculosis</i>
Letters in Drug Design & Discovery Beyond Providing Drugs: the Mectizan® Donation Stimulates New Strategies in Service Delivery and in Strengthening Health Systems
Current Pharmaceutical Biotechnology Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design